Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5199796 | 1.00 | TACR1 (0.72) | TACR1KCNH2 | |
| SCHEMBL5199792 | 1.00 | TACR1 (0.72) | TACR1KCNH2 | |
| SCHEMBL4946374 | 0.94 | TACR1 (0.70) | TACR1KCNH2 | |
| SCHEMBL4946379 | 0.94 | TACR1 (0.70) | TACR1KCNH2 | |
| SCHEMBL5199784 | 0.93 | TACR1 (0.64) | TACR1 | |
| SCHEMBL5197477 | 0.93 | TACR1 (0.64) | TACR1 | |
| SCHEMBL5197956 | 0.93 | TACR1 (0.64) | TACR1 | |
| SCHEMBL5197474 | 0.93 | TACR1 (0.64) | TACR1 | |
| SCHEMBL4941200 | 0.90 | TACR1 (0.67) | TACR1KCNH2 | |
| SCHEMBL4944034 | 0.90 | TACR1 (0.67) | TACR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1790636-A1 | PIPERIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060142337-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142337-A1 | Piperidine derivative and use thereof | AR, AHR, ARNT | TACR1 364/4885KCNH2 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.